Vera Therapeutics, Inc. (VERA) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	—	—	—	—	—
Cost of Revenue	—	—	—	—	(846.0K)
Gross Profit	—	—	—	—	846.0K
Operating Expenses
R&D Expense	261.9M	215.3M	126.2M	78.2M	69.8M
SG&A Expense	153.9M	100.2M	41.0M	23.8M	21.9M
General & Admin Expense	148.2M	100.2M	41.0M	23.8M	—
Selling & Marketing Expense	5.7M	—	—	—	—
Other Expenses	—	—	—	—	—
Total Operating Expenses	415.8M	315.5M	167.2M	102.0M	91.7M
Cost and Expenses	415.8M	315.5M	167.2M	102.0M	90.9M
Operating Income (EBIT)	(415.8M)	(315.5M)	(167.2M)	(102.0M)	(90.9M)
Non-Operating
Interest Income	23.0M	24.5M	20.7M	8.0M	1.8M
Interest Expense	7.5M	7.5M	7.6M	3.8M	992.0K
Net Interest Income	15.4M	16.9M	13.1M	4.2M	758.0K
Other Non-Op Income/Expense	13.9M	15.9M	15.0M	6.0M	1.8M
Non-Operating Income (excl Interest)	(21.4M)	(23.4M)	(22.6M)	(9.8M)	(2.8M)
EBT (Pre-Tax Income)	(401.9M)	(299.6M)	(152.1M)	(96.0M)	(89.1M)
Income Tax Expense	1.0K	1.0K	1.0K	1.0K	1.0K
Bottom Line
Net Income	(401.9M)	(299.6M)	(152.1M)	(96.0M)	(89.1M)
Earnings from Cont. Ops	(401.9M)	(299.6M)	(152.1M)	(96.0M)	(89.1M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(401.9M)	(299.6M)	(152.1M)	(96.0M)	(89.1M)
Per Share
Basic EPS	($5.86)	($4.66)	($2.75)	($2.25)	($3.35)
Diluted EPS	($5.86)	($4.66)	($2.75)	($2.25)	($3.35)
Revenue Per Share	$0.00	$0.00	$0.00	$0.00	$0.00
Shares
Basic Shares Outstanding	71.8M	64.2M	55.3M	42.7M	26.6M
Diluted Shares Outstanding	71.8M	64.2M	55.3M	42.7M	26.6M
Profitability Metrics
EBITDA	(393.8M)	(291.6M)	(144.4M)	(92.2M)	(88.9M)
D&A	536.0K	468.0K	105.0K	21.0K	(846.0K)
EBIT	(394.4M)	(292.1M)	(144.5M)	(92.2M)	(88.1M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026